Trial Profile
A study to assess whether two different doses of antenatal intravenous iron administration (500 mg and 1000mg ferric carboxymaltose) are equivalent in replenishing and sustaining iron stores successfully in pregnant iron deficient women
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Oct 2021
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- Acronyms PROTECTIVE
- 07 Oct 2021 Status changed from active, no longer recruiting to completed.
- 10 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 17 Sep 2015 New trial record